AKT1 and hepatocellular carcinoma: In HCC model, lupeol and S14161 (S14161, a newly identified PI3-Kinase inhibitor in vitro and in vivo) collaboratively suppressed tumor development while activating the PI3-kinase/AKT pathway, resulting in a tumor progression without adversely affecting body weight in a dose dependent manner.